Cancer Research and Treatment

Original Articles

Breast cancer

Retrospective Cohort Study on the Long-term Oncologic Outcomes of Sentinel Lymph Node Mapping Methods (Dye-Only versus Dye and Radioisotope Mapping) in Early Breast Cancer: A Propensity Score-Matched Analysis: Changjin Lim, Eunhye Kang, Ji Gwang Jung, Jong-Ho Cheun, Hong-Kyu Kim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han; Cancer Res Treat. 2023;55(2):562-569. Published online September 26, 2022; DOI: https://doi.org/10.4143/crt.2022.871

Abstract PDF PubReader ePub: Purpose
In sentinel lymph node (SLN) biopsy (SLNB) during breast cancer surgery, SLN mapping using dye and isotope (DUAL) may have lower false-negative rates than the dye-only (DYE) method. However, the long-term outcomes of either method are unclear. We aimed to compare long-term oncological outcomes of DYE and DUAL for SLNB in early breast cancer.
Materials and Methods
This retrospective single-institution cohort study included 5,795 patients (DYE, 2,323; DUAL, 3,472) with clinically node-negative breast cancer who underwent SLNB and no neoadjuvant therapy. Indigo carmine was used for the dye method and Tc99m-antimony trisulfate for the isotope. To compare long-term outcomes, pathologic N0 patients were selected from both groups, and propensity score matching (PSM), considering age, pT category, breast surgery, and adjuvant treatment, was performed (1,441 patients in each group).
Results
The median follow-up duration was 8.7 years. The median number of harvested sentinel nodes was 3.21 and 3.12 in the DYE and DUAL groups, respectively (p=0.112). The lymph node–positive rate was not significantly different between the two groups in subgroups of similar tumor sizes (p > 0.05). Multivariate logistic regression revealed that the mapping method was not significantly associated with the lymph node–positive rate (p=0.758). After PSM, the 5-year axillary recurrence rate (DYE 0.8% vs. DUAL 0.6%, p=0.096), and 5-year disease-free survival (DYE 93.9% vs. DUAL 93.7%, p=0.402) were similar between the two groups.
Conclusion
Dye alone for SLNB was not inferior to dual mapping regarding long-term oncological outcomes in early breast cancer.

4,119 View
109 Download

Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients: Mihong Choi, Jiyeon Han, Bo Ram Yang, Myoung-jin Jang, Miso Kim, Dae-Won Lee, Tae-Yong Kim, Seock-Ah Im, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee; Cancer Res Treat. 2021;53(1):65-76. Published online September 23, 2020; DOI: https://doi.org/10.4143/crt.2020.430

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer.
Materials and Methods
We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer.
Results
Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)–negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05).
Conclusion
Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies.

Citations

Citations to this article as recorded by

Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
Expert Review of Anticancer Therapy.2024; 24(6): 435. CrossRef
Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis
Xiaolin Jia, Ye Lu, Zili Xu, Qingqing Mu
Frontiers in Oncology.2023;[Epub] CrossRef
Effect of statins use on risk and prognosis of breast cancer: a meta-analysis
Guodong Zhao, Yanjun Ji, Qing Ye, Xin Ye, Guanqun Wo, Xi Chen, Xinyi Shao, Jinhai Tang
Anti-Cancer Drugs.2022; 33(1): e507. CrossRef
Studying the Cytotoxic Activity of Newly Designed and Synthesized HDAC Inhibitors Derivatives of Pentanoyl Anilide‐5‐Biguanide
Othman Makki Sagheer, Mohammed Hassan Mohammed, Jaafar S. Wadi, Zaid O. Ibraheem
Macromolecular Symposia.2022;[Epub] CrossRef
Metformin and Breast Cancer: Where Are We Now?
Mónica Cejuela, Begoña Martin-Castillo, Javier A. Menendez, Sonia Pernas
International Journal of Molecular Sciences.2022; 23(5): 2705. CrossRef
Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression
Giorgia Centonze, Dora Natalini, Alessio Piccolantonio, Vincenzo Salemme, Alessandro Morellato, Pietro Arina, Chiara Riganti, Paola Defilippi
Frontiers in Oncology.2022;[Epub] CrossRef
Synthesis of gamma biguanides butyric acid analogues as HDAC inhibitors and studying their cytotoxic activity
Othman Makki Sagheer, Mohammed Hassan Mohammed, Zaid O. Ibraheem, Jaafar S. Wadi, Mustafa F. Tawfeeq
Materials Today: Proceedings.2021; 47: 5983. CrossRef
Statins: a repurposed drug to fight cancer
Wen Jiang, Jin-Wei Hu, Xu-Ran He, Wei-Lin Jin, Xin-Yang He
Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef

8,870 View
209 Download
10 Web of Science
9 Crossref

Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test: Hee-Chul Shin, Han-Byoel Lee, Tae-Kyung Yoo, Eun-Shin Lee, Ryong Nam Kim, Boyoung Park, Kyong-Ah Yoon, Charny Park, Eun Sook Lee, Hyeong-Gon Moon, Dong-Young Noh, Sun-Young Kong, Wonshik Han; Cancer Res Treat. 2020;52(3):697-713. Published online February 4, 2020; DOI: https://doi.org/10.4143/crt.2019.559

Abstract PDF Supplementary Material PubReader ePub

Purpose
Hereditary cancer syndrome means that inherited genetic mutations can increase a person's risk of developing cancer. We assessed the frequency of germline mutations using an nextgeneration sequencing (NGS)–based multiple-gene panel containing 64 cancer-predisposing genes in Korean breast cancer patients with clinical features of hereditary breast and ovarian cancer syndrome (HBOC).
Materials and Methods
A total of 64 genes associated with hereditary cancer syndrome were selected for development of an NGS-based multi-gene panel. Targeted sequencing using the multi-gene panel was performed to identify germline mutations in 496 breast cancer patients with clinical features of HBOC who underwent breast cancer surgery between January 2002 and December 2017.
Results
Of 496 patients, 95 patients (19.2%) were found to have 48 deleterious germline mutations in 16 cancer susceptibility genes. The deleterious mutations were found in 39 of 250 patients (15.6%) who had breast cancer and another primary cancer, 38 of 169 patients (22.5%) who had a family history of breast cancer (≥ 2 relatives), 16 of 57 patients (28.1%) who had bilateral breast cancer, and 29 of 84 patients (34.5%) who were diagnosed with breast cancer at younger than 40 years of age. Of the 95 patients with deleterious mutations, 60 patients (63.2%) had BRCA1/2 mutations and 38 patients (40.0%) had non-BRCA1/2 mutations. We detected two novel deleterious mutations in BRCA2 and MLH1.
Conclusion
NGS-based multiple-gene panel testing improved the detection rates of deleterious mutations and provided a cost-effective cancer risk assessment.

Citations

Citations to this article as recorded by

Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine
Hyunwoo Lee, Yoon Ah Cho, Deok Geun Kim, Eun Yoon Cho
Cancer Research and Treatment.2024; 56(1): 149. CrossRef
Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing
Zhe Yu, Zirui Zhang, Jun Liu, Xiaoying Wu, Xiaojun Fan, Jiaohui Pang, Hua Bao, Jiani Yin, Xue Wu, Yang Shao, Zhengcheng Liu, Fang Liu
Molecular Oncology.2024; 18(5): 1301. CrossRef
Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand
Chalermkiat Kansuttiviwat, Pongtawat Lertwilaiwittaya, Ekkapong Roothumnong, Panee Nakthong, Peerawat Dungort, Chutima Meesamarnpong, Warisara Tansa-Nga, Khontawan Pongsuktavorn, Supakit Wiboonthanasarn, Warunya Tititumjariya, Nannipa Phuphuripan, Chittap
npj Genomic Medicine.2024;[Epub] CrossRef
Assessment of genome mutation analysis for tumor-informed detection of circulating tumor DNA in patients with breast cancer
Mugip Rahaman Abdul Wahab, Thirunavukkarasu Palaniyandi, Swarnakala Thamada, Sandhiya Viswanathan, Gomathy Baskar, Hemapreethi Surendran, P Baraneedharan, J Kannan, Maddaly Ravi, Suba Rajinikanth, Mohamed A. El-Tayeb, Shaban Syed
Clinica Chimica Acta.2024; 561: 119818. CrossRef
Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Savas, Balaji Virassamy, Megan M. R. O’Malley, Jasmine Kay, Scott N. Mueller, Laura K. Mackay, Roberto Salgado, Sherene Loi
Nature Reviews Cancer.2024; 24(8): 554. CrossRef
Genetic Testing Among Breast Cancer Patients in the Eastern Region of Saudi Arabia: Single-Center Experience
Ghadeer Al Ghareeb, Zainab Al Nass, Salma Abu-Grain, Alia Alnaji, Hani Almohanna, Hadi Al Shaikh Nasser, Saad Al Shahrani
Journal of Epidemiology and Global Health.2024; 14(3): 1351. CrossRef
Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis
Federico Anaclerio, Lucrezia Pilenzi, Anastasia Dell’Elice, Rossella Ferrante, Simona Grossi, Luca Maria Ferlito, Camilla Marinelli, Simona Gildetti, Giuseppe Calabrese, Liborio Stuppia, Ivana Antonucci
Frontiers in Genetics.2023;[Epub] CrossRef
Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies
Asad Mustafa Karim, Jeong Eun Kwon, Tanveer Ali, Jinsoo Jang, Irfan Ullah, Yeong-Geun Lee, Dae Won Park, Juha Park, Jin Woo Jeang, Se Chan Kang
Biochemical Pharmacology.2023; 212: 115545. CrossRef
Klinische Anwendungsbeispiele einer Next-Generation-Sequencing-basierten Multi-Genpanel-Analyse
Dietmar Enko, Erich Schaflinger, Daniel J. Müller
DMW - Deutsche Medizinische Wochenschrift.2023; 148(11): 695. CrossRef
A study of clinical and molecular characteristics in bilateral primary breast cancer
Bin Li, Weiqi Xu, Jianing Cao, Duancheng Guo, Zhonghua Tao, Juan Jin, Xichun Hu
Cancer Medicine.2023; 12(15): 15881. CrossRef
Klinische Anwendungsbeispiele einer Next-Generation-Sequencing-basierten Multi-Genpanel-Analyse
Dietmar Enko, Erich Schaflinger, Daniel J. Müller
TumorDiagnostik & Therapie.2023; 44(06): 401. CrossRef
Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients
Aysun Dauti Isiklar, Lamiya Aliyeva, Ahmet Yesilyurt, Aykut Soyder, Gul Basaran
Breast Cancer Research and Treatment.2023; 202(2): 297. CrossRef
Investigation of germline variants in Bahraini women with breast cancer using next-generation sequencing based-multigene panel
Ghada Al-Kafaji, Ghufran Jassim, Amani AlHajeri, Amna Mohamed Tayeb Alawadhi, Mariam Fida, Ibrahim Sahin, Faisal Alali, Elias Fadel, Amy McCart Reed
PLOS ONE.2023; 18(9): e0291015. CrossRef
Low prevalence of germline TP53 and PALB2 mutations in unselected cohort of breast cancer patients from Brunei Darussalam
Siti Nur Idayu Matusin, Zen Huat Lu, Mas Rina Wati Haji Abdul Hamid
F1000Research.2023; 12: 1537. CrossRef
Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel?
Erica L. Silver, Mariana Niell-Swiller
Current Opinion in Obstetrics & Gynecology.2022; 34(1): 36. CrossRef
The emerging roles of NGS in clinical oncology and personalized medicine
Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Abbas Salihi, Dana Khdr Sabir, Karzan R. Sidiq, Mohammed Fatih Rasul, Hazha Jamal Hidayat, Soudeh Ghafouri-Fard, Mohammad Taheri, Elena Jamali
Pathology - Research and Practice.2022; 230: 153760. CrossRef
Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition
P. Macquere, S. Orazio, F. Bonnet, N. Jones, V. Bubien, J. Chiron, D. Lafon, E. Barouk-Simonet, J. Tinat, L. Venat-Bouvet, P. Gesta, M. Longy, N. Sevenet
Journal of Human Genetics.2022; 67(6): 339. CrossRef
Novel Insights From the Germline Landscape of Breast Cancer in Brazil
Daniel Barbalho, Renata Sandoval, Erika Santos, Janina Pisani, Carla Quirino, Bernardo Garicochea, Benedito Rossi, Maria Isabel Achatz
Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment
Angela Secondino, Flavio Starnone, Iolanda Veneruso, Maria Di Tella, Serena Conato, Carmine De Angelis, Sabino De Placido, Valeria D’Argenio
Genes.2022; 13(4): 682. CrossRef
Multi-gene panel testing increases germline predisposing mutations’ detection in a cohort of breast/ovarian cancer patients from Southern Italy
Marcella Nunziato, Federica Di Maggio, Matilde Pensabene, Maria Valeria Esposito, Flavio Starnone, Carmine De Angelis, Alessandra Calabrese, Massimiliano D’Aiuto, Gerardo Botti, Sabino De Placido, Valeria D’Argenio, Francesco Salvatore
Frontiers in Medicine.2022;[Epub] CrossRef
Targeted Sequencing of Germline Breast Cancer Susceptibility Genes for Discovering Pathogenic/Likely Pathogenic Variants in the Jakarta Population
Sonar Soni Panigoro, Rafika Indah Paramita, Kristina Maria Siswiandari, Fadilah Fadilah
Diagnostics.2022; 12(9): 2241. CrossRef
Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study
Auhood Nassar, Abdel-Rahman N. Zekri, Mahmoud M. Kamel, Mostafa H. Elberry, Mai M. Lotfy, Mohamed G. Seadawy, Zeinab K. Hassan, Hany K. Soliman, Ahmed M. Lymona, Amira Salah El-Din Youssef
Genes.2022; 14(1): 106. CrossRef
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis
Renata Lazari Sandoval, Ana Carolina Rathsam Leite, Daniel Meirelles Barbalho, Daniele Xavier Assad, Romualdo Barroso, Natalia Polidorio, Carlos Henrique dos Anjos, Andréa Discaciati de Miranda, Ana Carolina Salles de Mendonça Ferreira, Gustavo dos Santos
PLOS ONE.2021; 16(2): e0247363. CrossRef
Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing
Zeng-Yun-Ou Zhang, Yuan-Yuan Wu, Xin-ying Cai, Wen-Liang Fang, Feng-Li Xiao
Frontiers in Genetics.2021;[Epub] CrossRef
Analysis of Sequence and Copy Number Variants in Canadian Patient Cohort With Familial Cancer Syndromes Using a Unique Next Generation Sequencing Based Approach
Pratibha Bhai, Michael A. Levy, Kathleen Rooney, Deanna Alexis Carere, Jack Reilly, Jennifer Kerkhof, Michael Volodarsky, Alan Stuart, Mike Kadour, Karen Panabaker, Laila C. Schenkel, Hanxin Lin, Peter Ainsworth, Bekim Sadikovic
Frontiers in Genetics.2021;[Epub] CrossRef
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
M. Bono, D. Fanale, L. Incorvaia, D. Cancelliere, A. Fiorino, V. Calò, A. Dimino, C. Filorizzo, L.R. Corsini, C. Brando, G. Madonia, A. Cucinella, R. Scalia, N. Barraco, F. Guadagni, E. Pedone, G. Badalamenti, A. Russo, V. Bazan
ESMO Open.2021; 6(4): 100235. CrossRef
Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations
Malwina Suszynska, Piotr Kozlowski
Genes.2020; 11(7): 798. CrossRef
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, Marco Bono, Alessia Fiorino, Valentina Calò, Chiara Brando, Lidia Rita Corsini, Nadia Barraco, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan
Cancers.2020; 12(9): 2415. CrossRef

13,588 View
553 Download
29 Web of Science
28 Crossref

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors: Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim; Cancer Res Treat. 2017;49(4):1153-1163. Published online February 27, 2017; DOI: https://doi.org/10.4143/crt.2016.463

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.

Citations

Citations to this article as recorded by

Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song
Breast Cancer Research and Treatment.2024; 206(3): 543. CrossRef
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin
Current Oncology.2023; 30(2): 1794. CrossRef
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study
Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk
Annals of Medicine & Surgery.2022;[Epub] CrossRef
Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis
Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias
Medicina.2021; 57(4): 385. CrossRef
Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control
Brändli SP, Palm J, Kowalewski MP, Reichler IM
Theriogenology.2021; 173: 73. CrossRef
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney
Cancer Management and Research.2021; Volume 13: 6537. CrossRef
Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results
Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid
Indian Journal of Surgical Oncology.2019; 10(3): 542. CrossRef
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, Sara Hurvitz
Clinical Cancer Research.2018; 24(21): 5206. CrossRef

12,448 View
362 Download
10 Web of Science
8 Crossref

Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery: Soo Kyung Ahn, Min Kyoon Kim, Jongjin Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, Young Joon Kang, Jisun Kim, Hyeong-Gon Moon, Jung Min Chang, Nariya Cho, Woo Kyung Moon, In Ae Park, Dong-Young Noh, Wonshik Han; Cancer Res Treat. 2017;49(4):1088-1096. Published online January 25, 2017; DOI: https://doi.org/10.4143/crt.2016.473

Abstract PDF Supplementary Material PubReader ePub

Purpose
The American College of Surgeons Oncology Group Z0011 trial reported that complete dissection of axillary lymph nodes (ALNs) may not be warranted in women with clinical T1-T2 tumors and one or two involved ALNs who were undergoing lumpectomy plus radiation followed by systemic therapy. The present study was conducted to identify preoperative imaging predictors of ≥ 3 ALNs.
Materials and Methods
The training set consisted of 1,917 patients with clinical T1-T2 and node negative invasive breast cancer. Factors associated with ≥ 3 involved ALNs were evaluated by logistic regression analysis. The validation set consisted of 378 independent patients. The nomogram was applied prospectively to 512 patients who met the Z0011 criteria.
Results
Of the 1,917 patients, 204 (10.6%) had ≥ 3 positive nodes. Multivariate analysis showed that involvement of ≥ 3 nodes was significantly associated with ultrasonographic and chest computed tomography findings of suspicious ALNs (p < 0.001 each). These two imaging criteria, plus patient age, were used to develop a nomogram calculating the probability of involvement of ≥ 3 ALNs. The areas under the receiver operating characteristic curve of the nomogram were 0.852 (95% confidence interval [CI], 0.820 to 0.883) for the training set and 0.896 (95% CI, 0.836 to 0.957) for the validation set. Prospective application of the nomogram showed that 60 of 512 patients (11.7%) had scores above the cut-off. Application of the nomogram reduced operation time and cost, with a very low re-operation rate (1.6%).
Conclusion
Patients likely to have ≥ 3 positive ALNs could be identified by preoperative imaging. The nomogram was helpful in selective intraoperative examination of sentinel lymph nodes.

Citations

Citations to this article as recorded by

Predicting three or more metastatic nodes using contrast-enhanced lymphatic US findings in early breast cancer
Zihan Niu, Yunxia Hao, Yuanjing Gao, Jing Zhang, Mengsu Xiao, Feng Mao, Yidong Zhou, Ligang Cui, Yuxin Jiang, Qingli Zhu
Insights into Imaging.2024;[Epub] CrossRef
Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with ≥ 3 positive sentinel lymph nodes based on machine-learning algorithms
Xiangli Xie, Yutong Fang, Lifang He, Zexiao Chen, Chunfa Chen, Huancheng Zeng, Bingfeng Chen, Guangsheng Huang, Cuiping Guo, Qunchen Zhang, Jundong Wu
BMC Cancer.2024;[Epub] CrossRef
Gail model and fifth edition of ultrasound BI‐RADS help predict axillary lymph node metastasis in breast cancer—A multicenter prospective study
Lu‐Ying Gao, Hai‐Tao Ran, You‐Bin Deng, Bao‐Ming Luo, Ping Zhou, Wu Chen, Yu‐Hong Zhang, Jian‐Chu Li, Hong‐Yan Wang, Yu‐Xin Jiang
Asia-Pacific Journal of Clinical Oncology.2023;[Epub] CrossRef
Nomogram based on multiparametric analysis of early‐stage breast cancer: Prediction of high burden metastatic axillary lymph nodes
Ling Li, Jing Zhao, Yu Zhang, Zhanyu Pan, Jin Zhang
Thoracic Cancer.2023; 14(35): 3465. CrossRef
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer
Jieying Chen, Xiaolian Su, Tingting Xu, Qifeng Luo, Lin Zhang, Guangyu Tang
Future Oncology.2022; 18(15): 1849. CrossRef
ACR Appropriateness Criteria® Imaging of the Axilla
Huong T. Le-Petross, Priscilla J. Slanetz, Alana A. Lewin, Jean Bao, Elizabeth H. Dibble, Mehra Golshan, Jessica H. Hayward, Charlotte D. Kubicky, A. Marilyn Leitch, Mary S. Newell, Christine Prifti, Matthew F. Sanford, John R. Scheel, Richard E. Sharpe,
Journal of the American College of Radiology.2022; 19(5): S87. CrossRef
Avoiding unnecessary intraoperative sentinel lymph node frozen section biopsy of patients with early breast cancer
Jongwon Kang, Tae-Kyung Yoo, Ahwon Lee, Jun Kang, Chang Ik Yoon, Bong Joo Kang, Sung Hun Kim, Woo Chan Park
Annals of Surgical Treatment and Research.2022; 102(5): 241. CrossRef
A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery
Young-Joon Kang, Jung Hyun Park, Young Wook Ju, Kyoung-Eun Kim, Yumi Kim, Eunshin Lee, Han-Byoel Lee, Dong-Young Noh, Wonshik Han
Scientific Reports.2022;[Epub] CrossRef
Accurate Evaluation of Feature Contributions for Sentinel Lymph Node Status Classification in Breast Cancer
Angela Lombardi, Nicola Amoroso, Loredana Bellantuono, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Daniele La Forgia, Vito Lorusso, Alfonso Monaco, Sabina Tangaro, Francesco Alfredo Zito, Roberto Bellotti, Raffaella Massafra
Applied Sciences.2022; 12(14): 7227. CrossRef
Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
Bhoowit Lerttiendamrong, Nattanan Treeratanapun, Voranaddha Vacharathit, Kasaya Tantiphlachiva, Phuphat Vongwattanakit, Sopark Manasnayakorn, Mawin Vongsaisuwon
Breast Cancer: Targets and Therapy.2022; Volume 14: 281. CrossRef
Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer
Sheng-Kai Geng, Shao-Mei Fu, Hong-Wei Zhang, Yi-Peng Fu
BMC Cancer.2022;[Epub] CrossRef
Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI
Su Min Ha, Jung Min Chang, Soo-Yeon Kim, Su Hyun Lee, Eun Sil Kim, Yeon Soo Kim, Nariya Cho, Woo Kyung Moon
Breast Cancer Research and Treatment.2021; 186(2): 463. CrossRef
Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study
Annarita Fanizzi, Domenico Pomarico, Angelo Paradiso, Samantha Bove, Sergio Diotaiuti, Vittorio Didonna, Francesco Giotta, Daniele La Forgia, Agnese Latorre, Maria Irene Pastena, Pasquale Tamborra, Alfredo Zito, Vito Lorusso, Raffaella Massafra
Cancers.2021; 13(2): 352. CrossRef
Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features
Annarita Fanizzi, Vito Lorusso, Albino Biafora, Samantha Bove, Maria Colomba Comes, Cristian Cristofaro, Maria Digennaro, Vittorio Didonna, Daniele La Forgia, Annalisa Nardone, Domenico Pomarico, Pasquale Tamborra, Alfredo Zito, Angelo Virgilio Paradiso,
Applied Sciences.2021; 11(21): 10372. CrossRef
The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
Eunjung Kong, Jungeun Choi
Nuclear Medicine Communications.2021; 42(12): 1369. CrossRef
Clinical Value of Axillary Ultrasonography in Breast Cancer with Lymph Node Metastases
Jung Ho Park, Hyun Ryung Kim, Sanghwa Kim, Young Ah Lim, Kyoonsoon Jung, Lee Su Kim
Journal of Surgical Ultrasound.2021; 8(2): 41. CrossRef
Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
V. Madekivi, P. Boström, A. Karlsson, R. Aaltonen, E. Salminen
Acta Oncologica.2020; 59(6): 689. CrossRef
External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
Antonio Piñero-Madrona, Francisco Ripoll-Orts, José Ignacio Sánchez-Méndez, Asunción Chaves-Benito, Maximiliano Rodrigo Gómez-de la Bárcena, Ana Calatrava-Fons, Salomón Menjón-Beltrán, Vicente Peg-Cámara
Breast Cancer Research and Treatment.2020; 181(2): 339. CrossRef
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Jung Min Chang, Jessica W. T. Leung, Linda Moy, Su Min Ha, Woo Kyung Moon
Radiology.2020; 295(3): 500. CrossRef
Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?
Martijn Leenders, Gaëlle Kramer, Kamar Belghazi, Katya Duvivier, Petrousjka van den Tol, Hermien Schreurs
Journal of Oncology.2019; 2019: 1. CrossRef
Computer-aided prediction model for axillary lymph node metastasis in breast cancer using tumor morphological and textural features on ultrasound
Woo Kyung Moon, I-Ling Chen, Ann Yi, Min Sun Bae, Sung Ui Shin, Ruey-Feng Chang
Computer Methods and Programs in Biomedicine.2018; 162: 129. CrossRef
The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer
Sofia E Triantafillidou
Hellenic Journal of Surgery.2018; 90(4): 186. CrossRef
Axillary Lymph Node to Primary Breast Tumor Standardized Uptake Value Ratio from FDG-PET/CT Imaging for Predicting the Necessity for Nodal Dissection in Primary Breast Tumors
Han-kyul Shin, Min Kyoon Kim, Sung Jun Park, Ju Won Seok, Hee-Chul Shin
Journal of Breast Disease.2017; 5(2): 76. CrossRef

10,577 View
355 Download
21 Web of Science
23 Crossref

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea: Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im; Cancer Res Treat. 2017;49(2):454-463. Published online August 23, 2016; DOI: https://doi.org/10.4143/crt.2016.259

Abstract PDF PubReader ePub

Purpose
Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)–positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients.
Materials and Methods
This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment historywere extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity.
Results
The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated.
Conclusion
Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

Citations

Citations to this article as recorded by

Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
Josee-Lyne Ethier, Danielle N. Desautels, Eitan Amir, Helen MacKay
Gynecologic Oncology.2017; 147(1): 158. CrossRef

12,402 View
249 Download
1 Web of Science
1 Crossref

Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer: Tae-Kyung Yoo, Wonshik Han, Hyeong-Gon Moon, Jisun Kim, Jun Woo Lee, Min Kyoon Kim, Eunshin Lee, Jongjin Kim, Dong-Young Noh; Cancer Res Treat. 2016;48(3):962-969. Published online October 22, 2015; DOI: https://doi.org/10.4143/crt.2015.173

Abstract PDF PubReader ePub

Purpose
Previous studies examining the relationship between time to treatment and survival outcome in breast cancer have shown inconsistent results. The aim of this study was to analyze the overall impact of delay of treatment initiation on patient survival and to determine whether certain subgroups require more prompt initiation of treatment.
Materials and Methods
This study is a retrospective analysis of stage I-III patients who were treated in a single tertiary institution between 2005 and 2008. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to evaluate the impact of interval between diagnosis and treatment initiation in breast cancer and various subgroups.
Results
A total of 1,702 patients were included. Factors associated with longer delay of treatment initiation were diagnosis at another hospital, medical comorbidities, and procedures performed before admission for surgery. An interval between diagnosis and treatment initiation as a continuous variable or with a cutoff value of 15, 30, 45, and 60 days had no impact on disease-free survival (DFS). Subgroup analyses for hormone-responsiveness, triple-negative breast cancer, young age, clinical stage, and type of initial treatment showed no significant association between longer delay of treatment initiation and DFS.
Conclusion
Our results show that an interval between diagnosis and treatment initiation of 60 days or shorter does not appear to adversely affect DFS in breast cancer.

Citations

Citations to this article as recorded by

Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics
Yu-Tung Teng, Yong Alison Wang, Yaa-Hui Dong, Jason J. Liu
Breast Cancer Research and Treatment.2024; 205(3): 619. CrossRef
Surgical management of breast cancer in Victoria: A state‐wide audit
Nakjun Sung, Arun Muthusamy, Norah Finn, Ella Stuart, Jane Fox, Belinda Yeo
Asia-Pacific Journal of Clinical Oncology.2023; 19(4): 499. CrossRef
Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)
Raíra Mesquita Maschmann, Rafaela Gomes De Jesus, Gustavo Werutsky, Taiane Francieli Rebelatto, Geraldo Queiroz, Sergio Daniel Simon, José Bines, Carlos Henrique Escosteguy Barrios, Daniela Dornelles Rosa
Breast Cancer Research and Treatment.2023; 198(1): 123. CrossRef
Benefits versus drawbacks of delaying surgery due to additional consultations in older patients with breast cancer
Brian L. Egleston, Richard J. Bleicher, Carolyn Y. Fang, Thomas J. Galloway, Slobodan Vucetic
Cancer Reports.2023;[Epub] CrossRef
Time interval between breast cancer diagnosis and surgery is associated with disease outcome
Siji Zhu, Shuai Li, Jiahui Huang, Xiaochun Fei, Kunwei Shen, Xiaosong Chen
Scientific Reports.2023;[Epub] CrossRef
Factors Associated with the Nutritional Status of Women with Non-Metastatic Breast Cancer in a Brazilian High Complexity Oncology Center
Roberto Júnio Gomes Silva, Wesley Rocha Grippa, Luiz Claudio Barreto Silva Neto, Oscar Geovanny Enriquez-Martinez, Júlia Anhoque Cavalcanti Marcarini, Raphael Manhães Pessanha, Fabiano Kenji Haraguchi, Luís Carlos Lopes-Júnior
Nutrients.2023; 15(23): 4961. CrossRef
Factors Associated With Breast Cancer Surgery Delay Within a Coordinated Multihospital Community Health System: When Does Surgical Delay Impact Outcome?
Judy A. Tjoe, Kayla Heslin, Ana C. Perez Moreno, Shanita Thomas, Jessica J.F. Kram
Clinical Breast Cancer.2022; 22(1): e91. CrossRef
Factors Affecting Time to Surgery in Breast Cancer Patients
Anees B. Chagpar, Marissa Howard-McNatt, Akiko Chiba, Edward A. Levine, Jennifer S. Gass, Kristalyn Gallagher, Sharon Lum, Ricardo Martinez, Allric I. Willis, Andrew Fenton, Naveenraj L. Solomon, Magi Senthil, David Edmonson, Jukes P. Namm, Laura Walters,
The American Surgeon™.2022; 88(4): 648. CrossRef
Breast Cancer Care Timeliness Framework: A Quality Framework for Cancer Control
Noor Mastura Mohd Mujar, Maznah Dahlui, Nor Aina Emran, Imisairi Abdul Hadi, Yang Wai Yan, Sarojah Arulanantham, Chan Hooi Chea, Nur Aishah Mohd Taib
JCO Global Oncology.2022;[Epub] CrossRef
Time-to-treatment initiation for cutaneous melanoma reflects disparities in healthcare access in Brazil: a retrospective study
G.D. Pereira Shimada, A. Archanjo da Mota, M. Carvalho de Souza, S.S. Bernardes
Public Health.2022; 210: 1. CrossRef
Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan
Nai-Chen Shih, Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai
Scientific Reports.2022;[Epub] CrossRef
Prognostic factors and outcomes in women with breast cancer in Slovenia in relation to step-wise implementation of organized screening
Sonja Tomšič, Tina Žagar, Ana Mihor, Miran Mlakar, Katarina Lokar, Katja Jarm, Vesna Zadnik, Edward Jay Trapido
PLOS ONE.2022; 17(11): e0278384. CrossRef
Perfis Social e Previdenciário: Influência na Qualidade de Vida dos Pacientes submetidos à Radioterapia
Stella Grigolette Rodrigues , Lilian Chessa Dias, Marielza Regina Ismael Martins
Revista Brasileira de Cancerologia.2022;[Epub] CrossRef
A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic
Brett A. Johnson, Anthony C. Waddimba, Gerald O. Ogola, James W. Fleshman, John T. Preskitt
The American Journal of Surgery.2021; 222(2): 311. CrossRef
Determinants of delay from cancer diagnosis to treatment initiation in a cohort of brazilian women with breast cancer
Giselle C. Medeiros, Luiz C. S. Thuler, Anke Bergmann
Health & Social Care in the Community.2021; 29(6): 1769. CrossRef
Impact of delayed treatment in women diagnosed with breast cancer: A population‐based study
Peh Joo Ho, Alex R. Cook, Nur Khaliesah Binte Mohamed Ri, Jenny Liu, Jingmei Li, Mikael Hartman
Cancer Medicine.2020; 9(7): 2435. CrossRef
The Waiting Game: How Long Are Breast Cancer Patients Waiting for Definitive Diagnosis?
Alexandra Kovar, Michael Bronsert, Kshama Jaiswal, Colleen Murphy, Dulcy Wolverton, Gretchen Ahrendt, Sarah Tevis
Annals of Surgical Oncology.2020; 27(10): 3641. CrossRef
“First Do No Harm”: Significance of Delays from Diagnosis to Surgery in Patients with Non‐metastatic Breast Cancer
Jennifer Xu, Luke Bromley, Grace Chew, Belinda Yeo
World Journal of Surgery.2020; 44(11): 3812. CrossRef
Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer
Pamela Minicozzi, Liesbet Van Eycken, Florence Molinie, Kaire Innos, Marcela Guevara, Rafael Marcos‐Gragera, Clara Castro, Elisabetta Rapiti, Alexander Katalinic, Ana Torrella, Tina Žagar, Magdalena Bielska‐Lasota, Paolo Giorgi Rossi, Nerea Larrañaga, Joa
International Journal of Cancer.2019; 144(9): 2118. CrossRef
Vulnerabilidade social e câncer de mama: diferenciais no intervalo entre o diagnóstico e o tratamento em mulheres de diferentes perfis sociodemográficos
Ana Lúcia Lobo Vianna Cabral, Luana Giatti, Claudina Casale, Mariângela Leal Cherchiglia
Ciência & Saúde Coletiva.2019; 24(2): 613. CrossRef
Relecture systématique des bilans radiologiques extérieurs de diagnostic du cancer du sein : une valeur ajoutée
Juliette Boudier, Guillaume Oldrini, Philippe Henrot, Julia Salleron, Anne Lesur
Bulletin du Cancer.2019; 106(4): 316. CrossRef
Patient and Care Delays of Breast Cancer in China
Yue-Lin Li, Ya-Chao Qin, Lu-Ying Tang, Yu-Huang Liao, Wei Zhang, Xiao-Ming Xie, Qiang Liu, Ying Lin, Ze-Fang Ren
Cancer Research and Treatment.2019; 51(3): 1098. CrossRef
The influence on survival of delay in the treatment initiation of screening detected non-symptomatic breast cancer
Yan Li, Yidong Zhou, Feng Mao, Jinghong Guan, Yan Lin, Xuejing Wang, Yanna Zhang, Xiaohui Zhang, Songjie Shen, Qiang Sun
Scientific Reports.2019;[Epub] CrossRef
Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population‐based cohort study
Louise Eriksson, Jonas Bergh, Keith Humphreys, Fredrik Wärnberg, Sven Törnberg, Kamila Czene
International Journal of Cancer.2018; 143(5): 1093. CrossRef

12,537 View
209 Download
30 Web of Science
24 Crossref

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane: Hyeon Kang Koh, Kyung Hwan Shin, Kyubo Kim, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Eui Kyu Chie, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee, Seock-Ah Im, Sung Whan Ha; Cancer Res Treat. 2016;48(2):483-490. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2015.111

Abstract PDF PubReader ePub

Purpose
This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. Materials and Methods From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome.
Results
The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. Conclusion RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.

Citations

Citations to this article as recorded by

MiR-210 regulates lung adenocarcinoma by targeting HIF-1α
Guolei Cao, Peiwen Fan, Ronghui Ma, Qinghe Wang, Lili He, Haiwen Niu, Qin Luo
Heliyon.2023; 9(5): e16079. CrossRef
Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
European Journal of Cancer.2022; 174: 153. CrossRef
Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women
Oluwole Adeyemi Babatunde, Jan M. Eberth, Tisha Felder, Robert Moran, Samantha Truman, James R. Hebert, Jiajia Zhang, Swann Arp Adams
Journal of Racial and Ethnic Health Disparities.2021; 8(1): 147. CrossRef
How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
Lu Cao, Cheng Xu, Gang Cai, Wei-Xiang Qi, Rong Cai, Shu-Bei Wang, Dan Ou, Min Li, Kun-Wei Shen, Jia-Yi Chen
Annals of Surgical Oncology.2021; 28(4): 2155. CrossRef
Saving the Breast Saves the Lives of Breast Cancer Patients
Mohammad Esmaeil Akbari, Maryam Khayamzadeh, Hamid Reza Mirzaei, Afshin Moradi, Atieh Akbari, Farid Moradian, Neda Khalili
International Journal of Surgical Oncology.2020; 2020: 1. CrossRef
Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis
Si-Ye Chen, Yu Tang, Shu-Lian Wang, Yong-Wen Song, Hui Fang, Jian-Yang Wang, Hao Jing, Jiang-Hu Zhang, Guang-Yi Sun, Xu-Ran Zhao, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning Lu, Hua Ren, Zi-Hao Yu, Ye-Xiong Li
Frontiers in Oncology.2020;[Epub] CrossRef
Evaluation of tissue computed tomography number changes and dosimetric shifts after conventional whole-breast irradiation in patients undergoing breast-conserving surgery
Joo Hwan Lee, Dong Soo Lee, So Hyun Park, Young Kyu Lee, Jeong Soo Kim, Yong Seok Kim
Tumor Biology.2018; 40(8): 101042831879188. CrossRef
The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
Marissa C van Maaren, Reini W Bretveld, Jan J Jobsen, Renske K Veenstra, Catharina GM Groothuis-Oudshoorn, Hendrik Struikmans, John H Maduro, Luc JA Strobbe, Philip MP Poortmans, Sabine Siesling
British Journal of Cancer.2017; 117(2): 179. CrossRef

11,377 View
126 Download
10 Web of Science
9 Crossref

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea: Moo Hyun Lee, Wonshik Han, Jeong Eon Lee, Ku Sang Kim, Heeseung Park, Jongjin Kim, Soo Youn Bae, Hyun Joo Shin, Jong Won Lee, Eun Sook Lee; Cancer Res Treat. 2015;47(2):208-214. Published online September 11, 2014; DOI: https://doi.org/10.4143/crt.2013.223

Abstract PDF PubReader ePub

Purpose
The 21-gene (Oncotype DX) recurrence score (RS) assay is useful in predicting the benefits of adjuvant chemotherapy for early breast cancer patients and is widely used in Western countries. However, to date, it has not gained much popularity in East Asia. We analyzed the results from five institutions’ experience from using the 21-gene assay and examined the impact of assay results on decision making of chemotherapy in Korean breast cancer patients and the associations between RS and clinicopathologic characteristics.
Materials and Methods
The 21-gene assay was performed on 212 patients with estrogen receptor-positive early breast cancer in five institutions. Each center made systemic treatment decisions both before and after the knowledge of assay results.
Results
Among the 212 patients, 132 (62.3%) had a low RS of < 18, 60 (28.3%) had an intermediate RS of 18-30, and 20 (9.4%) had a high RS of ≥ 31. Histologic grade, presence of micrometastases, Ki-67, and presence of lymphatic invasion were statistically associated with the RS results. Treatment decisions were changed in 115 of 212 patients (54.2%) in 109 of 212 (51.4%) from chemotherapy plus hormone therapy to hormone therapy, and in six of 212 (2.8%) from hormone therapy to chemotherapy plus hormone therapy.
Conclusion
The 21-gene breast cancer assay proved to have a significant impact on treatment decision- making. The test reduces chemotherapy use in more than 50% of Korean estrogen receptor-positive, early breast cancer patients.

Citations

Citations to this article as recorded by

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang
Cancers.2023; 15(3): 903. CrossRef
Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen
British Journal of Cancer.2021; 124(5): 975. CrossRef
Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada
Simon Gagnet, Caroline Diorio, Louise Provencher, Cynthia Mbuya-Bienge, Julie Lapointe, Claudya Morin, Julie Lemieux, Hermann Nabi
Journal of Personalized Medicine.2021; 11(9): 858. CrossRef
Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
Bradley M. Turner, Hani Katerji, Huina Zhang, David G. Hicks
Human Pathology Reports.2021; 26: 300574. CrossRef
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im
Clinical Breast Cancer.2020; 20(2): 98. CrossRef
Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer
Yufei Zeng, Weiqi Gao, Lin Lin, Xiaosong Chen, Kunwei Shen
Journal of Geriatric Oncology.2020; 11(5): 843. CrossRef
Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters
Jeongmin Lee, Sung Hun Kim, Bong Joo Kang
Scientific Reports.2020;[Epub] CrossRef
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool
Anna Olsson-Brown, Pavlos Piskilidis, Julie O'Hagan, Nicky Thorp, Peter Robson, Helen Innes, Helen Wong, Silvia Cicconi, Richard Jackson, Tamara Kiernan, Christopher Holcombe, Susan O'Reilly, Carlo Palmieri
The Breast.2019; 44: 94. CrossRef
Clinical significance of 21-gene recurrence score assay for hormone receptor–positive, lymph node-negative breast cancer in early stage
Yang Yu-qing, Wang Lei, Huang Mei-ling, Xiao Jing-jing, Wei Mei-chen, Wu Jiang, Hao Jun-sheng, Ling Rui, Li Nan-lin
Experimental and Molecular Pathology.2019; 108: 150. CrossRef
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein, Janet Brown
Health Technology Assessment.2019; 23(30): 1. CrossRef
Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer
Megan C. Roberts, Allison W. Kurian, Valentina I. Petkov
Journal of the National Comprehensive Cancer Network.2019; 17(6): 662. CrossRef
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Yikyung Park
Breast Cancer Research.2019;[Epub] CrossRef
Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer
Lizhe Zhu, Nan Ma, Bin Wang, Can Zhou, Yu Yan, Ke Wang, Jianjun He, Yu Ren
Oncology Letters.2019;[Epub] CrossRef
Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
E.J. Blok, E. Bastiaannet, W.B. van den Hout, G.J. Liefers, V.T.H.B.M. Smit, J.R. Kroep, C.J.H. van de Velde
Cancer Treatment Reviews.2018; 62: 74. CrossRef
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
Jae-Myung Kim, Jai Min Ryu, Isaac Kim, Hee Jun Choi, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Jeong Eon Lee
Journal of Breast Cancer.2018; 21(2): 222. CrossRef
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay
Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee
Breast Cancer Research and Treatment.2018; 170(1): 69. CrossRef
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
Jonathan Chen, Xian Wu, Paul J. Christos, Silvia Formenti, Himanshu Nagar
Breast Cancer Research.2018;[Epub] CrossRef
Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer
Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim
Breast Cancer Research and Treatment.2018; 172(3): 627. CrossRef
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Jinkyoung Kim, Aeree Kim, Chungyeul Kim
Oncology Letters.2018;[Epub] CrossRef
Impact d’un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire : une expérience française
C. Dreyfus, M. Ballester, J. Gligorov, P. Agranat, M. Antoine, I. Tengher, A. Bricou
Gynécologie Obstétrique & Fertilité.2015; 43(12): 780. CrossRef

12,838 View
127 Download
24 Web of Science
20 Crossref

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy: Min Kyoon Kim, Wonshik Han, Hyeong-Gon Moon, Soo Kyung Ahn, Jisun Kim, Jun Woo Lee, Ju-Yeon Kim, Taeryung Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, In Ae Park, Dong-Young Noh; Cancer Res Treat. 2015;47(2):197-207. Published online September 4, 2014; DOI: https://doi.org/10.4143/crt.2013.247

Abstract PDF PubReader ePub

Purpose
The ability to accurately predict the likelihood of achieving breast conservation surgery (BCS) after neoadjuvant chemotherapy (NCT) is important in deciding whether NCT or surgery should be the first-line treatment in patients with operable breast cancers. Materials and Methods We reviewed the data of 513 women, who had stage II or III breast cancer and received NCT and surgery from a single institution. The ability of various clinicopathologic factors to predict the achievement of BCS and tumor size reduction to ≤ 3 cm was assessed. Nomograms were built and validated in an independent cohort. Results BCS was performed in 50.1% of patients, with 42.2% of tumors reduced to ≤ 3 cm after NCT. A multivariate logistic regression analysis showed that smaller initial tumor size, longer distance between the lesion and the nipple, absence of suspicious calcifications on mammography, and a single tumor were associated with BCS rather than mastectomy (p < 0.05). Negative estrogen receptor, smaller initial tumor size, higher Ki-67 level, and absence of in situ component were associated with residual tumor size ≤ 3 cm (p < 0.05). Two nomograms were developed using these factors. The areas under the receiver operating characteristic curves for nomograms predicting BCS and residual tumor ≤ 3 cm were 0.800 and 0.777, respectively. The calibration plots showed good agreement between the predicted and actual probabilities. Conclusion We have established a model with novel factors that predicts BCS and residual tumor size after NCT. This model can help in making treatment decisions for patients who are candidates for NCT.

Citations

Citations to this article as recorded by

Risk scoring system for predicting breast conservation after neoadjuvant chemotherapy
Lobna Ouldamer, Sofiane Bendifallah, Joseph Pilloy, Flavie Arbion, Gilles Body, Caroline Brisson, Vincent Lavoué, Jean Lévêque, Emile Daraï
The Breast Journal.2019; 25(4): 696. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Cancer Research and Treatment.2018; 50(4): 1260. CrossRef
Development of Nomogram to Predict the Best Military Category Using Physical Fitness Variables: A Model Development in Navy Trainees
Milad Nazarzadeh, Ali Reza Khoshdel, Abolfazl Goodarzi, Alireza Mosavi Jarrahi
Journal of Archives in Military Medicine.2018;[Epub] CrossRef
Predicting Successful Conservative Surgery after Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Chang Seok Ko, Kyu Min Kim, Jong Won Lee, Han Shin Lee, Sae Byul Lee, Guiyun Sohn, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Byung Ho Son, Seung Do Ahn, Sung-Bae Kim, Hak Hee Kim, Sei Hyun Ahn
Journal of Breast Disease.2018; 6(2): 52. CrossRef
External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis
Ludivine Genre, Henri Roché, Léonel Varela, Dorra Kanoun, Monia Ouali, Thomas Filleron, Florence Dalenc
European Journal of Cancer.2017; 72: 200. CrossRef
Facteurs prédictifs de traitement conservateur après chimiothérapie néo-adjuvante dans le cancer du sein
J. Pilloy, C. Fleurier, M. Chas, L. Bédouet, M.L. Jourdan, F. Arbion, G. Body, L. Ouldamer
Gynécologie Obstétrique Fertilité & Sénologie .2017; 45(9): 466. CrossRef
Actual Conversion Rate from Total Mastectomy to Breast Conservation after Neoadjuvant Chemotherapy for Stages II–III Breast Cancer Patients
Hyejin Mo, Yumi Kim, Jiyoung Rhu, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im, Eun-Shin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Dong-Young Noh, Wonshik Han
Journal of Breast Disease.2017; 5(2): 51. CrossRef

14,262 View
100 Download
4 Web of Science
7 Crossref

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions: Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Wonshik Han, Kyubo Kim, Eui Kyu Chie, In-Ae Park, Young Tae Kim, Dong-Young Noh, Sung Whan Ha, Yung-Jue Bang; Cancer Res Treat. 2014;46(3):280-287. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.280

Abstract PDF PubReader ePub

Purpose
A newly isolated mediastinal lymph node (LN) or a small pulmonary nodule, which appears during breast cancer surveillance, may pose a diagnostic dilemma with regard to malignancy. We conducted this study to determine which clinical factors were useful for the differentiation of malignant lesions from benign lesions under these circumstances. Materials and Methods We enrolled breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule that arose during surveillance, and whose lesions were pathologically confirmed. Tissue diagnosis was made by mediastinoscopy, video-assisted thoracic surgery or thoracotomy. Results A total of 43 patients were enrolled (mediastinal LN, 13 patients; pulmonary nodule, 30 patients). Eighteen patients (41.9%) were pathologically confirmed to have a benign lesion (benign group), and 25 patients (58.1%) were confirmed to have malignant lesion (malignant group). Between the two groups, the initial tumor size (p=0.096) and N stage (p=0.749) were similar. Hormone receptor negativity was more prevalent in the malignant group (59.1% vs. 40.9%, p=0.048). The mean lesion size was larger in the malignant group than in the benign group (20.8 mm vs. 14.4 mm, p=0.024). Metastatic lesions had a significantly higher value of maximal standardized uptake (mSUV) than that of benign lesions (6.4 vs. 3.4, p=0.021). Conclusion Hormone receptor status, lesion size, and mSUV on positron emission tomography are helpful in the differentiation of malignant lesions from benign lesions in breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule during surveillance.

Citations

Citations to this article as recorded by

Unusual metastases of breast cancer: a single-center retrospective study
Pınar ÖZDEMİR AKDUR, Nazan ÇİLEDAĞ
The European Research Journal.2023; 9(6): 1444. CrossRef
18Fluorodeoxyglucose‐positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment
Lei Zhu, Haiman Bian, Lieming Yang, Jianjing Liu, Wei Chen, Xiaofeng Li, Jian Wang, Xiuyu Song, Dong Dai, Zhaoxiang Ye, Wengui Xu, Xiaozhou Yu
Thoracic Cancer.2019; 10(5): 1086. CrossRef

12,703 View
60 Download
2 Web of Science
2 Crossref

Case Report

Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review: Miso Kim, Dae-Won Lee, Jin Im, Koung Jin Suh, Bhumsuk Keam, Hyeong-Gon Moon, Seock-Ah Im, Wonshik Han, In Ae Park, Dong-Young Noh; Cancer Res Treat. 2014;46(1):93-97. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.93

Abstract PDF PubReader ePub

Adenoid cystic carcinoma (ACC) of the breast is a very rare and indolent tumor with a favorable prognosis, despite its triple-negative status. Due to its rarity, there has been no consensus regarding treatments, and treatment guidelines have not been established. Here, we report on six patients with ACC of the breast. All of the patients initially presented with localized disease and no axillary lymph node metastases. Although some of our patients developed local recurrence or distant metastases, all patients had a favorable clinical course, and to date, none of the patients has died from complications of her disease. Here, we described the clinicopathologic features of ACC of the breast and review the current literature.

Citations

Citations to this article as recorded by

MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple‐negative breast cancers
Harsh Batra, Priya S C Bose, Yang Ding, Alan Dai, Hui Chen, Constance T Albarracin, Hongxia Sun, Aysegul A Sahin, Fei Yang, Ignacio I Wistuba, Maria G Raso
Histopathology.2024; 85(3): 503. CrossRef
Adenoid Cystic Carcinoma of the Breast: Multimodality Imaging Findings and Review of the Literature
Nilgun Guldogan, Gul Esen, Yasemin Kayadibi, Fusun Taskin, Aysenur Oktay Alfatli, Fatma Nur Soylu Boy, Pinar Balci, Onur Bugdayci, Fatma Tokat, Tulin Ozturk, Mehtap Tunaci, Akif Enes Arikan
Academic Radiology.2023; 30(6): 1107. CrossRef
Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast
Tao Huang, Qigen Fang, Lianjie Niu, Lina Wang, Xianfu Sun
Scientific Reports.2023;[Epub] CrossRef
Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature
Joanna Rypel, Paulina Kubacka, Joanna Mykała-Cieśla, Jacek Pająk, Weronika Bulska-Będkowska, Jerzy Chudek
Medicina.2023; 59(11): 2005. CrossRef
Adenoid Cystic Carcinoma of the Breast and Intraoperative Electron Radiotherapy: Single Case Report and Review of Literature
Giuseppe Accardo, Alba ML Capobianco, Giuseppe La Torre, Alexios Thodas, Graziella Marino, Leuconoe Grazia Sisti, Giulia Vita
Future Oncology.2022; 18(7): 871. CrossRef
Breast adenoid cystic carcinoma: a report of seven cases and literature review
Meilin Zhang, Yanbiao Liu, Hongguang Yang, Feng Jin, Ang Zheng
BMC Surgery.2022;[Epub] CrossRef
Adenoid cystic carcinoma and basaloid carcinoma of the breast: A clinicopathological study
Vicente Marco, Felip Garcia, Isabel T. Rubio, Teresa Soler, Laura Ferrazza, Ignasi Roig, Inmaculada Mendez, Xavier Andreu, Clarisa González Mínguez, Francesc Tresserra
Revista Española de Patología.2021; 54(4): 242. CrossRef
Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study
Wenxiang Zhang, Yi Fang, Zhihui Zhang, Jing Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Adenoid Cystic Carcinoma of the Breast
Yun-Chung Cheung, Shir-Hwa Ueng, Shu-Hang Ng, Wen-Lin Kuo
Current Medical Imaging Formerly Current Medical Imaging Reviews.2021; 17(4): 539. CrossRef
Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
Gábor Cserni, Cecily M. Quinn, Maria Pia Foschini, Simonetta Bianchi, Grace Callagy, Ewa Chmielik, Thomas Decker, Falko Fend, Anikó Kovács, Paul J. van Diest, Ian O. Ellis, Emad Rakha, Tibor Tot
Cancers.2021; 13(22): 5694. CrossRef
Adenoid Cystic Carcinoma Breast: a Rare Entity
Santosh Tummidi, Shubhra Prasad, Deepti Joshi, Ashwani Tandon, Anjaly Mohan, Pradeep Saxena, Neelkamal Kapoor
Indian Journal of Surgical Oncology.2020; 11(S2): 226. CrossRef
Adenoid cystic carcinoma of the breast
Devon N Thomas, Armand Asarian, Philip Xiao
Journal of Surgical Case Reports.2019;[Epub] CrossRef
Adenoid cystic carcinoma of the breast in a male
Wenyang Pang, Zhengyi Wang, Xiaoyan Jin, Qiang Zhang
Medicine.2019; 98(32): e16760. CrossRef
An unusual presentation of adenoid cystic carcinoma of the breast with metastatic disease in the clavicle
Thomas Edward Glover, Ryan Butel, Cara Manmeet Bhuller, Emma Louise Senior
BJR|case reports.2017; 3(2): 20160119. CrossRef
Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
Hasnae Alaoui Mhamdi, Hampig Raphael Kourie, Christiane Jungels, Philippe Aftimos, Rhizlane Belbaraka, Martine Piccart-Gebhart
Journal of Medical Case Reports.2017;[Epub] CrossRef
Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials
Patrick M. Dillon, Samhita Chakraborty, Christopher A. Moskaluk, Prashant J. Joshi, Christopher Y. Thomas
Head & Neck.2016; 38(4): 620. CrossRef
Pleomorphic adenoma‐like tumour of the breast
Emad A Rakha, Mohammed A Aleskandarany, Rehab M Samaka, Zsolt Hodi, Andrew H S Lee, Ian O Ellis
Histopathology.2016; 68(3): 405. CrossRef
Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management
Emad A Rakha, Sunil Badve, Vincenzo Eusebi, Jorge S Reis‐Filho, Stephen B Fox, David J Dabbs, Thomas Decker, Zsolt Hodi, Shu Ichihara, Andrew HS Lee, José Palacios, Andrea L Richardson, Anne Vincent‐Salomon, Fernando C Schmitt, Puay‐Hoon Tan, Gary M Tse,
Histopathology.2016; 68(1): 45. CrossRef
A rare case of adenoid cystic carcinoma of the breast detected by 18F-FDG PET/CT
G. Treglia, F. Bertagna, L. Ceriani, L. Giovanella
Revista Española de Medicina Nuclear e Imagen Molecular.2015; 34(3): 205. CrossRef
A rare case of adenoid cystic carcinoma of the breast detected by 18F-FDG PET/CT
G. Treglia, F. Bertagna, L. Ceriani, L. Giovanella
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2015; 34(3): 205. CrossRef
Radiologic and Pathological Correlation of Adenoid Cystic Carcinoma of the Breast: A Case Report
Jung Gyu Kim, Shin Young Kim, Hae Yoen Jung, Sung Yong Kim, Deuk Young Lee, Sang Hyun Park
Journal of the Korean Society of Radiology.2015; 72(6): 411. CrossRef
Imaging Manifestation of Adenoid Cystic Carcinoma of the Breast
Wei Tang, Wei Jun Peng, Ya Jia Gu, Hui Zhu, Ting Ting Jiang, Can Li
Journal of Computer Assisted Tomography.2015; 39(4): 523. CrossRef
Adenoid cystic carcinoma of the breast from a single-center cohort
Elizabeth Kander, Sania Raza, Sagar Dhamne, Mariana Solari, Sarika Jain
Cancer Treatment Communications.2015; 4: 182. CrossRef
Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology
Emad A. Rakha, Andrew H.S. Lee, Rachael Sheeran, Chris Abbosh, Zsolt Hodi, Will Merchant, Ian O. Ellis, Abeer M. Shaaban
Pathobiology.2015; 82(3-4): 172. CrossRef
Influence of Ribosomal Protein L39-L in the Drug Resistance Mechanisms of Lacrimal Gland Adenoid Cystic Carcinoma Cells
Qing Ye, Shao-Feng Ding, Zhi-An Wang, Jie Feng, Wen-Bin Tan
Asian Pacific Journal of Cancer Prevention.2014; 15(12): 4995. CrossRef
Adenoid cystic carcinoma of breast: Recent advances
Kosuke Miyai
World Journal of Clinical Cases.2014; 2(12): 732. CrossRef

15,860 View
102 Download
26 Web of Science
26 Crossref

First
Prev
Page of 1
Next
Last

Search